NASDAQ:VCYTVeracyte Stock Price, Forecast & News

Veracyte's stock was trading at $23.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VCYT stock has increased by 13.5% and is now trading at $26.73. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veracyte.

Veracyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Veracyte.

Veracyte Inc (NASDAQ:VCYT) issued its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.06. The biotechnology company had revenue of $31.12 million for the quarter, compared to analyst estimates of $30.31 million. Veracyte had a negative net margin of 18.36% and a negative return on equity of 9.68%. View Veracyte's earnings history.

Veracyte updated its first quarter 2020 After-Hours earnings guidance on Thursday, April, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $30.5-31.5 million, compared to the consensus revenue estimate of $30.35 million.

3 equities research analysts have issued 12-month price objectives for Veracyte's stock. Their forecasts range from $30.00 to $35.00. On average, they expect Veracyte's share price to reach $32.33 in the next twelve months. This suggests a possible upside of 21.0% from the stock's current price. View analysts' price targets for Veracyte.

News headlines about VCYT stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Veracyte earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Veracyte.

Veracyte saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 5,410,000 shares, an increase of 5.0% from the May 31st total of 5,150,000 shares. Based on an average daily trading volume, of 516,900 shares, the short-interest ratio is presently 10.5 days. Approximately 11.3% of the company's shares are sold short. View Veracyte's Current Options Chain.

Some companies that are related to Veracyte include Natera (NTRA), InVitae (NVTA), ELEKTA AB/ADR (EKTAY), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Centogene (CNTG), Personalis (PSNL), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Biocept (BIOC), Celcuity (CELC), Anpac Bio-Medical Science (ANPC) and Miragen Therapeutics (MGEN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), CA (CA), Crispr Therapeutics (CRSP), AbbVie (ABBV), Advanced Micro Devices (AMD), Endologix (ELGX), BlackRock (BLK), InVitae (NVTA), Gilead Sciences (GILD) and Alibaba Group (BABA).

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCYT stock can currently be purchased for approximately $26.73.

Veracyte has a market capitalization of $1.34 billion and generates $120.37 million in revenue each year. The biotechnology company earns $-12,600,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Veracyte employs 270 workers across the globe.

The official website for Veracyte is www.veracyte.com.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]